ABSTRACT B7-H1 is a novel B7 family protein attributed to costimulatory and immune regulatory functions. Here we report that human myoblasts cultured from control subjects and patients with inflammatory myopathies as well as TE671 muscle rhabdomyosarcoma cells express high levels of B7-H1 after stimulation with the inflammatory cytokine IFN-γ. Coculture experiments of MHC class I/II-positive myoblasts with CD4 and CD8 T cells in the presence of antigen demonstrated the functional consequences of muscle-related B7-H1 expression: production of inflammatory cytokines, IFN-γ and IL-2, by CD4 as well CD8 T cells was markedly enhanced in the presence of a neutralizing anti-B7-H1 antibody. This observation was paralleled by an augmented expression of the T cell activation markers CD25, ICOS, and CD69, thus showing B7-H1-mediated inhibition of T cell activation. Further, we investigated 23 muscle biopsy specimens from patients with polymyositis (PM), inclusion body myositis (IBM), dermatomyositis (DM), and nonmyopathic controls for B7-H1 expression by immunohistochemistry: B7-H1 was expressed in PM, IBM, and DM specimens but not in noninflammatory and nonmyopathic controls. Staining was predominantly localized to areas of strong inflammation and to muscle cells as well as mononuclear cells. These data highlight the immune regulatory properties of muscle cells and suggest that B7-H1 expression represents an inhibitory mechanism induced upon inflammatory stimuli and aimed at protecting muscle fibers from immune aggression.
observed under pathological conditions (1) (2) (3) . Muscle-related expression of the classical MHC antigens MHC class I and MHC class II has been taken as evidence for the interaction of muscle with CD8 cytotoxic T cells and CD4 T-helper cells in idiopathic inflammatory myopathies (4, 5) . Muscle cells can present antigens to CD4 T cells (6) and are considered to express adhesion as well as costimulatory molecules including a yet unidentified candidate associated with the B7 family but distinct from CD80 (B7.1) and CD86 (B7.2; refs 7-10). Interactions of B7 family members with their respective receptors on T cells critically influence all stages of immune responses, with B7.1/2/CD28 costimulation being essential for the generation of antigen-specific T cells during primary immune responses. As the expression of B7.1/2 is mainly restricted to hematopoetic cells, the identification of novel members of the extended B7 family and their receptors sheds more light on how nonlymphoid tissues exert an immunobiological role (11) (12) (13) (14) . B7-H1, or programmed death-1 ligand (PD-L1), is a type I transmembrane protein with 20% amino acid identity to B7.1 and 15% amino acid identity to B7.2. Costimulation of T cells with B7-H1-Fc fusion protein induces T cell proliferation and the secretion of IL-10 and IFN-γ (15) . Recently, however, it has been suggested that B7-H1 negatively regulates cytokine synthesis (16, 17) . B7-H1 exhibits a broader tissue distribution than B7.1/2 (CD80/CD86) (16, (18) (19) (20) and regulates immune responses by interacting with programmed death-1 (PD-1) and other non-PD-1 receptors on activated T cells (11-14, 21, 22) . PD-1 contains an immune receptor tyrosine-based inhibitory motif (ITIM), and coligation of PD-1 and the TCR leads to rapid phosphorylation of SHP-2, a phosphatase suggested to attenuate TCR signaling (23) . PD-L2 (also termed B7-DC) was recently identified as a second ligand for PD-1 and is predominantly expressed on dendritic cells (DC; 24, 25) . Again, there are contrasting results regarding its function, either characterized as mainly inhibitory (16) or stimulatory (26) .
MATERIALS AND METHODS

Antibodies and reagents
The following primary antibodies were used: anti-human B7-H1 (clone 5H1; IgG 1 isotype; ref 21) , anti-ICOS (F44; generously provided by R. A. Kroczek, Robert Koch Insitut Berlin, Germany), anti-HLA-A2 (BB7.2, ATCC, Manassas, VA), and anti-MHC I (W6/32), anti-MHC II (L243), anti-CD3 (OKT3), anti-CD4 (RPA-T4), anti-CD8 (B9.11), anti-CD11b (BEAR1), anti-CD14 (B-A8), anti-CD56 (anti-NCAM, MY31), anti-CD80 (BB-1), anti-CD86 (B-T7), and anti-pan-α/β−ΤCR (T10B9.1A-31) (all from BD PharMingen, Heidelberg, Germany). Secondary antibodies and isotype controls were as follows: goat anti-mouse F(ab) 2 -di-chlorotriazinylfluoresceine (DTAF), goat anti-mouse-PE IgG (H+L) F(ab´) 2 fragment (Dianova, Hamburg, Germany), mouse IgG1κ (MOPC-21, Sigma, St. Louis, MO), and mouse IgG (Linaris, Wertheim, Germany). All antibodies were titrated for flow cytometry. A final concentration of 6 µg/ml anti-B7-H1 (5H1) was used for blocking experiments. IFN-γ and tumor necrosis factor-α (TNF-α) were from Peprotech EC Ltd (London, England). Normal goat serum was from Dianova, human IgG (Alphaglobin®) was obtained from Grifols (Langen, Germany), glatiramer acetate (GA) was obtained from Teva Pharmaceutical Industries (Petah Tiqva, Israel), phythemagglutinine (PHA-L) was from Biochrom KG (Berlin, Germany), and Superantigens (staphylococcal enterotoxin B, staphylococcal enterotoxin A, and toxic shock syndrome toxin-1), all were from Toxin Technology (Sarasota, FL) and were used as a SAg mix (10 pg/ml each).
Clinical material
Diagnostic muscle biopsy specimens were obtained from patients with inflammatory myopathies [polymyositis (PM), n=6: age range 51-89 yr; dermatomyositis (DM), n=5: age range 61-70 yr; inclusion body myositis (IBM), n=6: age range 58-80 yr] and nonmyopathic controls (n=6, age range: 20-62 yr). Written consent was obtained from all donors, and tissue sampling was approved by the local ethics committee.
Immunohistochemical studies
Flash-frozen muscle biopsy specimens were cut into 8-10 µm cryostat sections and analyzed by immunohistochemistry. Acetone-fixed air-dried sections were blocked and incubated with primary antibodies or corresponding nonimmune IgG isotype controls, diluted in PBS containing 2% bovine serum albumin for 45 min at concentrations optimized by titrating the respective primary antibodies. The reaction product was visualized with the streptavidin-biotin method (reagents from DAKO, Hamburg, Germany) using diaminobenzidine (Serva, Heidelberg, Germany) as an electron donor. Alternatively, antibody binding was visualized by immunofluorescence microscopy (CY3-or FITC-labelled secondary antibodies, Dianova). Tonsil was used as a positive control for B7-H1 expression.
Cell isolation and culture
Myoblasts were isolated from normal subjects or patients with inflammatory myopathies, purified by magnetic bead separation and cultured as described previously (27) . Myoblasts stained >95% positive for the neural cell adhesion molecule (NCAM) by flow cytometry. TE671 rhabdomyosarcoma cells were obtained from ATCC. Human HLA-DR4 transfectants of TE671 cells were kindly provided by N. Willcox (Oxford, UK). TE671-DR4 cells were cultured in RPMI1640 medium supplemented with 1% glutamine (Gibco Life Technologies, Paisley, UK), 10% fetal calf serum (FCS; Fetal Calf Serum Gold, PAA Laboratories, Linz, Austria), and penicillin (100 IU/ml)/streptomycin (100 µg/ml; Gibco) containing 0.15 mg/ml hygromycin (Sigma) and 0.75 mg/ml G418. Peripheral blood mononuclear cells (PBMC) were isolated from peripheral blood of healthy volunteers by density gradient centrifugation using PAA Separating Solution (PAA Laboratories GmbH). Monocytes were depleted by adhesion to plastic flasks for 1 h. Monocytes, >90% pure, as assessed by flow cytometry, were cultured in RPMI 10% FCS supplemented with GM-CSF (100 ng/ml, Leukomax, Sandoz, Germany) and IL-4 (40 ng/ml, PeproTech Inc). After 6 days, the cells exhibited an immature DC phenotype (CD14-CD1a+ MHC-IIlow CD86low CD80low/-CD83-). Maturation was induced by incubation of the immature DCs with LPS (5 µg/ml, S. thyphi, Sigma L-7261). High levels of surface MHC class II and costimulatory molecules (CD86, CD80) identified mature DC. CD4 and CD8 T cells (>95%) were purified by positive selection with CD4 or CD8 Microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). cDNA from purified thymic epithelial cells, which were used as control cells, was kindly provided by E. Tolosa (Tübingen, Germany).
Cytokine induction and flow cytometry
For analysis of surface molecules and coculture experiments, myoblasts or TE671 cells were cultured in the presence of 500 U/ml IFN-γ or 500 U/ml TNF-α or both as indicated. Adherent cells were detached nonenzymatically using cell dissociation buffer (Invitrogen™, Heidelberg, Germany). All cells were washed with FACS® buffer containing PBS with 0.1% bovine serum albumin and 0.1% sodium azide. To minimize binding to Fc receptors, PBMC, purified T cells, and myoblasts were blocked with human immunoglobulins at 1.25 mg/ml for 10 min at 4°C. After one wash step, the unlabeled or labeled first antibody was added. Isotype control monoclonal antibodies were used at the same concentration as the primary antibodies. Incubation was done on ice for 45 min, followed by two washes. Goat anti-mouse IgG [F(ab) 2 -PE (5 µg/ml, Sigma)] was used as secondary antibody. Histograms of stained cells were analyzed by calculating the specific fluorescence index (SFI: geometric mean of specific antibody divided by geometric mean of isotype control antibody). For labeled PBMC or T cell subsets, quadrant analysis of dot blots was done.
Coculture experiments of myoblasts and T cells
Myoblasts were plated in 24-well plates (Costar, Bodenheim, Germany) at a density of 1.25 x 10 5 and cultured in the absence or presence of IFN-γ (500 U/ml) for 48 h to induce MHC class II and B7-H1 expression. After the cells were washed, 1 x 10 6 freshly purified T cells (CD4, CD8) were added in the presence of SAg mix (10 pg/ml) or GA (100 µg/ml). Cells subsequently were cocultured in RPMI1640 medium. Where indicated, anti-B7-H1 (5H1) or an isotype control antibody was added to the cocultures to delineate functional relevance of B7-H1 for muscleimmune cell interactions. For measurement of cytokine production (human IFN-γ, IL-2), supernatants were removed at the times indicated and analyzed by standard ELISA (BD Pharmingen). For measurement of T cell activation markers, cells were harvested at times indicated and subjected for flow cytometry.
RNA extraction, cDNA synthesis and PCR
Total RNA extraction was performed using peqGOLD Tri Fast™ isolation reagent (peqLab, Erlangen, Germany). For first-strand cDNA synthesis, 2.5 µg total RNA were dissolved in 21.5 µl DEPC-treated H 2 O dd. . Two microliters of random hexamers (200 ng/µl) were added to each sample before incubation at 70°C for 10 min. Samples were cooled on ice and subjected to a mixture consisting of 5x M-MLV RT-buffer (10 µl/sample, Promega, Madison, WI), dNTP (10 mM, 10 µl/sample), RNAsin (40 U/µl, 0.25 µl/sample, Promega), M-MLV RT (200 U/µl, 1 µl/sample, Promega), and DEPC-treated H 2 O dd (5.25 µl/sample). This mixture of 26.5 µl was added to each RNA/random hexamer solution. Samples were mixed and incubated for 10 min at room temperature, then 50 min at 42°C, and finally 15 min at 70°C.
For conventional PCR, 1 µl of cDNA was used to amplify the products of interest in a 20 µl standard-PCR-reaction; 18S RNA was amplified as a control. Specificity of amplification was confirmed by direct DNA sequencing of extracted bands after reamplification. For quantitative real-time PCR (QRT-PCR), measurement of gene expression was performed utilizing the ABI prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA). The HUSAR Genius software package (DKFZ, Heidelberg, Germany) was used to design the primers for amplification. Primers (BioChip Technologies GmbH, Freiburg, Germany) were designed when possible to span exon-exon junctions in order to prevent amplification of genomic DNA and to result in amplicons <150 bp to enhance efficiency of PCR amplification. Relative quantification of specific gene expression was performed by two-step real-time PCR using cDNA as a template. Templates were multiplied using PE Applied Biosystems (Perkin Elmer) SYBR® Green PCR Master Mix [containing hot-start-AmpliTaqGold®, SYBR Green PCR buffer (2x), MgCl 2 , and dNTP]. RT-PCR of cDNA specimens was conducted in a total volume of 15 µl with 1x Taq Man Master Mix (Perkin-Elmer) with primers at optimized concentrations. Thermal cycler parameters were 2 min at 50°C, 10 min at 95°C, and 40 cycles of denaturation at 95°C for 15 s followed by annealing/extension at 60°C for 1 min. The fluorescence resulting from binding of SYBR Green dye to double-stranded DNA was measured directly in the PCR reaction tube. Data were analyzed with the ABI PRISM® Detection System using the comparative C T (threshold cycle) method (Applied Biosystems, User Bulletin). Samples were normalized to 18S rRNA to account for the variability in the initial concentration of the total RNA and conversion efficiency of the RT reaction. Product specificity of the PCR products and quality of primers were confirmed by agarose gel electrophoresis, sequencing of bands, and dissociation curve analysis. The internal reference dye ROX included in the PCR buffer was used to check for fluorescence fluctuations caused by changes in concentration or volume. All PCR assays were performed in duplicates. Real-time monitoring of fluorescent emission from cleavage of sequence specific probes by the nuclease activity of Taq polymerase allowed definition of the threshold cycle during the exponential phase of amplification. Standard curves generated for each gene had excellent PCR amplification efficiency (90-100%) as determined by the slope of the standard curves. Linear regression analysis of all standard curves was 0.99. 
RESULTS
IFN-γ-inducible B7-H1 protein in TE671 rhabdomyosarcoma cells and in cultured human myoblasts
TE671 muscle rhabdomyosarcoma cells (TE671 wild-type cells, TE671-DR4 transfectants) were examined for expression of B7-H1. TE671 constitutively express MHC-I and, in the case of TE671-DR4, MHC-II (data not shown). TE671 did not express B7-H1 constitutively but strongly upregulated the cell surface expression of B7-H1 in response to IFN-γ with a maximum expression at 72 h (Fig. 1A) . TNF-α had no effect on B7-H1 expression (data not shown). Five lines of cultured myoblasts from different donors were examined for B7-H1 expression. In all experiments, myoblasts were over 95% positive for NCAM (CD56), which serves as a reliable marker for myoblasts (ref 28; and Fig. 1B) . No differences were observed between myoblasts derived from patients with inflammatory myopathies and nonmyopathic control subjects. As reported previously, myoblasts constitutively express MHC-I. MHC-II is induced by IFN-γ but not TNF-α (ref 3; Fig. 1B) . In analogy to TE671, unstimulated cultured myoblasts did not express B7-H1 in four of five myoblast preparations from different donors. IFN-γ strongly induced cell surface expression of B7-H1 in all myoblast lines, whereas TNF-α alone had no effect on B7-H1 protein expression (Fig. 1B) . When IFN-γ and TNF-α were added together, a synergistic effect on upregulation was observed (data not shown). Human myoblasts showed a similar kinetic of upregulation as TE671 cells (data not shown). In contrast to B7-H1, neither cultured myoblasts nor TE671 cells expressed B7.1 (CD80) or B7.2 (CD86) protein under any condition (data not shown).
To corroborate the protein data, we analyzed total RNA from purified cultured myoblasts for different B7 molecule transcripts by QRT-PCR. Human myoblasts did not express CD80 or CD86 mRNA ( Fig. 2A and B) . Corresponding to the protein data ( Fig. 1) , mRNA for B7-H1 was virtually absent in unstimulated myoblasts, whereas IFN-γ or IFN-γ plus TNF-α induced B7-H1 (PD-L1) mRNA expression by a factor of 30.3 to 92.7 (Fig. 2C) . mRNA levels of PD-L2 were slightly upregulated after treatment with IFN-γ or IFN-γ plus TNF-α (factor 2.50 to 3.95; Fig.  2D ).
Inhibition of T cell activation by B7-H1 on human myoblasts and TE671 cells
To assess the functional consequences of B7-H1 expression on muscle cells, we performed coculture experiments with freshly purified allogeneic CD4 and CD8 T cells and assessed the modulation of T cell cytokine production and cell surface marker expression of T cell activation by B7-H1. Myoblasts were induced to express B7-H1 and MHC-II by IFN-γ and subsequently cocultured with CD4 or CD8 T cells and antigen (SAg, GA) in the presence of neutralizing anti-B7-H1 mAb 5H1 or isotype control antibodies. The release of IFN-γ and IL-2 into the supernatant was measured at the times indicated. Absolute levels of cytokines produced differed between donors (IFN-γ: mean value 1160 pg/ml for CD4, 527 pg/ml for CD8; IL-2: mean value 344 pg/ml for CD4; 49 pg/ml for CD8; all values in the presence of the isotype control antibody). Anti-B7-H1 mAb 5H1 strongly augmented the production of IFN-γ and IL-2 by CD4 as well CD8 T cells compared with the isotype control antibody (factor 1.3 to 6.3; Fig. 3A) . Kinetic experiments were performed to investigate the effect of B7-H1 blockade at 24, 48, and 72 h of coculture. The maximum effect of B7-H1 blockade for the augmentation of IFN-γ and IL-2 release was observed at 48 h, with no further change at 72 h of coculture (data not shown). The inhibitory effect of B7-H1 was also demonstrated by assessing the expression pattern of T cell activation markers after coculture in the presence or absence of a neutralizing B7-H1 antibody. Neutralization of B7-H1 led to increased expression levels of CD25, CD69, and ICOS on CD4 as well as CD8 T cells, thus demonstrating the inhibitory role of muscle-related B7-H1 for T cell activation ( Fig. 3B and C) . Experiments with TE671 and TE671-DR4 cells yielded similar results corroborating the inhibitory effect of B7-H1 expression for T cell activation (data not shown).
B7-H1 expression in inflamed muscle tissue in vivo
Muscle biopsy specimens from patients with PM (n=6), IBM (n=5), and DM (n=6) and from nonmyopathic and noninflammatory controls (n=6) were examined for B7-H1 expression by immunohistochemistry. MHC class I and CD8 immunoreactivity was assessed in parallel (Fig. 4  and data not shown) . No B7-H1 expression was detected on six muscle biopsy specimens from nonmyopathic controls or noninflammatory myopathies. In contrast, B7-H1 expression was detectable in inflammatory myopathies (PM: 6 of 6; IBM: 5 of 6; DM: 5 of 6; Fig. 4) . Musclerelated expression of B7-H1 was observed on the surface and to some extent in the cytoplasm of muscle fibers. It was localized in areas where inflammatory cells lay in close apposition to damaged or nonnecrotic muscle fibers. B7-H1-positive muscle fibers were in direct contact with mononuclear cells including T cells, corroborating the assumption of the in vivo relevance of B7-H1 and its receptor interactions in inflammatory muscle disorders. Some regenerating or degenerating muscle fibers also showed B7-H1 staining (Fig. 4) . Of note, mononuclear cells within the inflammatory tissue sections reflecting B cells, monocytes, or T cells also stained positive for B7-H1 (ref 15 ; Fig. 4) . Further, some muscle capillaries in proximity to inflammatory infiltrates, especially in DM, exhibited B7-H1 immunoreactivity (data not shown).
DISCUSSION
Insights in the immune regulatory properties of muscle are of high importance for a better understanding of desirable and undesirable immune reactions occurring in this tissue. Muscle fibers and myoblasts interact with immune cells (e.g., refs 6, 27, 29) and may thus play an important role in the inciting or perpetuating events of muscle-derived or muscle-directed immune responses (reviewed in refs 4, 30, 31 ). Here we demonstrate that muscle cells express B7-H1, a novel member of the B7 family of costimulatory molecules. TE671 muscle rhabdomyosarcoma cells and cultured human myoblasts show high levels of B7-H1 mRNA and protein after stimulation with the inflammatory cytokine IFN-γ (Figs. 1 and 2) . In biopsy specimens of inflammatory myopathies, B7-H1 expression was detected on muscle fibers in areas characterized by the presence of inflammatory cells and muscle fiber damage (Fig. 4) . Interestingly, B7-H1 expressed on muscle cells was found to be a potent inhibitor of CD4 and CD8 T cell function, as it reduced cytokine production and expression of T cell activation markers in cocultures of muscle cells with lymphocytes in the presence of antigen (Fig. 3) .
The demonstration of muscle-related B7-H1 expression together with its functional consequences for muscle-immune cell interactions advances the understanding of immune regulatory mechanisms promoted by muscle cells. In general, costimulatory signals play a key role in regulating T cell activation and have decisive influence in cellular effector mechanisms of various inflammatory conditions, including autoimmune diseases (reviewed in 11-14, 32). Whereas B7.1/2/CD28 interactions have been studied extensively during the last years in various animal models as well as in human disease, the immunological role of novel members of the B7 family such as B7-H1 is far from being completely understood. Muscle fibers and cultured myoblasts do not express B7.1 (CD80) or B7.2 (CD86) protein under normal or inflammatory conditions (refs 8-10, 33; Fig. 2 ) but nonetheless modulate antigen-specific T cell responses. Muscle cells have therefore been postulated to express other costimulatory molecules, including a yet unidentified B7-related costimulatory protein (BB-1) that interacts with CD28/CTLA-4 and putatively has stimulatory functions on T cell activation (8, 9) . The important advance of the present work is the identification of a molecularly defined B7-costimulatory molecule expressed on muscle. Our data achieved in vitro and in vivo suggest an important immunobiological role B7-H1 in the context of autoimmune myopathies. However, because of its expression patterns in vivo, the receptor interaction of B7-H1 with PD-1 and other non-PD-1 receptors, but not CD28/CTLA-4, and the functional role of the B7-H1 pathway for T cell activation, it is highly unlikely that this molecule represents the yet unidentified costimulatory molecule BB-1 in muscle cells (8, 9) .
What might be the role of B7-H1 in muscle? B7-H1/PD-1 interactions have been hypothesized to play a prominent role in inhibiting effector or memory T cell responses especially under conditions of low antigenic stimulation and relative independence from CD28 costimulation (16) . In nonprofessional antigen-presenting cells such as muscle, B7-H1 expression might be a protective mechanism activated in response to immune-mediated damage of MHC-expressing target cells and provoked by inflammatory cytokines like IFN-γ. The expression patterns of B7-H1 observed in inflammatory myopathies together with our functional experiments support this view (Fig. 4) . Muscle fibers are believed to be the primary target of the immune attack in PM, an assumption that has been substantiated by data showing 1) a focused T cell repertoire in PM (34, 35) , 2) the vectorial orientation of perforin in direction toward muscle fibers (36), 3) the recognition of a muscle-related antigen by a T cell receptor derived from a PM lesion (37) , and 4) the inflammation after muscle-specific upregulation of MHC class I molecules in a mouse model (38) . Evidence for the capability of muscle to promote immunoprotective mechanisms has recently been demonstrated as well: the nonclassical MHC molecule HLA-G protects muscle fibers from the immune-mediated lysis and thus represents a mechanism by which muscle might effectively counterbalance immune damage (3, 27) . The observation that muscle-related B7-H1 inhibits cytotoxic CD8 T cell as well as CD4 T-helper functions is of particular importance in this context: B7-H1 expressed on muscle fibers could directly interfere with cytotoxic T cell effector functions and inhibit the production of effector cytokines by interaction with CD4 effector/memory cells in vivo. However, conclusions on the possible role of B7-H1 in muscle disease in vivo, based on the present functional data in vitro, remain still speculative at present.
The observation of muscle-related expression of B7-H1 has broad implications as it could play an important role in various immune reactions that occur in this tissue. As hypothesized, B7-H1 could protect muscle fibers from cell-mediated injury in autoimmune muscle disorders (PM, DM or IBM) or in different muscle infections. Further, B7-H1 could modulate the immune responses after protein-or DNA-based vaccinations and efficiently reduce muscle-directed antigen-specific and non-antigen-specific immune responses in either conditions. Our data provide evidence for the strong capability of muscle to promote immunoprotective or immune suppressive mechanisms and support a concept proposing that the expression of B7-H1 in the periphery may regulate local levels of immune inflammation. of cytokine production by B7-H1 expressed on cultured human myoblasts was demonstrated by coculture experiments with allogeneic CD4 and CD8 T-cells in the presence of antigen (superantigen, SAg; glatirameracetate, GA). Myoblasts were cultured in the presence of IFN-γ (500 U/ml) for 48 h to upregulate MHC-I, MHC-II, and B7-H1 expression. CD4 T cells (CD4) or CD8 T cells (CD8) were added in the presence of an IgG 1 isotype control antibody (MOPC-21) or anti-B7-H1 mAb (5H1). Cytokine release was assessed by ELISA 48 h later. Data are expressed as mean relative change of cytokine production compared with the isotype control from 3-8 independent experiments. B, C) Modulation of T-cell activation marker expression by B7-H1 was assessed by flow cytometry. CD25, CD69, and ICOS protein expression on T-cells were determined after 48 h coculture of human myoblasts with allogeneic CD4 (B) or CD8 T-cells (C) by flow cytometry using PE-labeled mAb anti-ICOS, anti-CD25, and anti-CD69. Myoblasts were cultured under the same conditions as indicated in A. Dot blots show expression of T-cell activation markers and the influence of neutralizing B7-H1 compared with the isotype control. Four independent experiments were performed; B and C show 1 representative experiment. 
